Improving metabolic conditions An estimated 75% of people with obesity have nonalcoholic fatty liver disease and 34% have MASH, or metabolic dysfunction-associated steatohepatitis, according to researchers with the German drugmaker Boehringer Ingelheim
Data was collected from secondary care institutions
Start your intake How GLP-1 Changes Your Calorie Needs GLP-1 medications activate receptors in your brain and gut that regulate hunger and fullness
For patients with a history of kidney stones, GLP1 medications remain a safe option when hydration is prioritized
When integrated with hormone optimization, nutrition, resistance training, and restorative sleep, microdosing offers a potential pathway to extend healthspan, not just lifespanallowing women to age with energy, cognitive vitality, and cardiovascular resilience.
Membership includes consultations with licensed medical providers and ongoing care team support